메뉴 건너뛰기




Volumn 121, Issue 5, 2009, Pages 68-81

Beyond glycemic control: Treating the entire type 2 diabetes disorder

Author keywords

DPP 4; Exenatide; GLP 1; Liraglutide; Type 2 diabetes mellitus; Weight

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

EID: 78549284992     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.09.2054     Document Type: Review
Times cited : (20)

References (78)
  • 1
  • 2
    • 77649083118 scopus 로고    scopus 로고
    • Management
    • American Diabetes Association Burant CF, ed. 6th ed. Alexandria, VA: American Diabetes Association
    • American Diabetes Association. Management. In: Burant CF, ed. Medical Management of Type 2 Diabetes. 6th ed. Alexandria, VA: American Diabetes Association; 2008:33-85.
    • (2008) Medical Management of Type 2 Diabetes , pp. 33-85
  • 3
    • 43449108812 scopus 로고    scopus 로고
    • Economic costs of diabetes in the U.S. in 2007
    • American Diabetes Association
    • American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615.
    • (2008) Diabetes Care , vol.31 , Issue.3 , pp. 596-615
  • 4
    • 28944435295 scopus 로고    scopus 로고
    • Accessed May 26, 2009
    • International Diabetes Federation. Diabetes prevalence. http://www.idf.org/home/index.cfm?node=264. Accessed May 26, 2009.
    • Diabetes Prevalence
  • 5
    • 42349087252 scopus 로고    scopus 로고
    • Microvacular and macrovascular complications of diabetes
    • Fowler MJ. Microvacular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77-82.
    • (2008) Clin Diabetes , vol.26 , Issue.2 , pp. 77-82
    • Fowler, M.J.1
  • 6
    • 0035897696 scopus 로고    scopus 로고
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
    • (2001) JAMA , vol.285 , Issue.19 , pp. 2486-2497
  • 8
    • 74249123740 scopus 로고    scopus 로고
    • GLP-1 analogues, DPP-IV inhibitors, and the metabolic syndrome
    • Fonseca V, ed. Oxford, UK: Atlas Medical Publishing
    • Stonehouse AH, Holcombe H, Kendall DM. GLP-1 analogues, DPP-IV inhibitors, and the metabolic syndrome. In Fonseca V, ed. Therapeutic Strategies in Metabolic Syndrome. Oxford, UK: Atlas Medical Publishing; 2008:137-157.
    • (2008) Therapeutic Strategies in Metabolic Syndrome , pp. 137-157
    • Stonehouse, A.H.1    Holcombe, H.2    Kendall, D.M.3
  • 9
    • 50949120052 scopus 로고    scopus 로고
    • Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality
    • Ho JS, Cannaday JJ, Barlow CE, Mitchell TL, Cooper KH, FitzGerald SJ. Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality. Am J Cardiol. 2008;102(6):689-692.
    • (2008) Am J Cardiol , vol.102 , Issue.6 , pp. 689-692
    • Ho, J.S.1    Cannaday, J.J.2    Barlow, C.E.3    Mitchell, T.L.4    Cooper, K.H.5    FitzGerald, S.J.6
  • 10
    • 57249103368 scopus 로고    scopus 로고
    • Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: An observational study in 13 087 patients
    • Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13 087 patients. Diabetologia. 2009;52(1):65-73.
    • (2009) Diabetologia , vol.52 , Issue.1 , pp. 65-73
    • Eeg-Olofsson, K.1    Cederholm, J.2    Nilsson, P.M.3
  • 11
    • 49649083150 scopus 로고    scopus 로고
    • Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study
    • Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008;31(8):1582-1584.
    • (2008) Diabetes Care , vol.31 , Issue.8 , pp. 1582-1584
    • Fox, C.S.1    Pencina, M.J.2    Wilson, P.W.3    Paynter, N.P.4    Vasan, R.S.5    D'Agostino Sr., R.B.6
  • 12
    • 0035514956 scopus 로고    scopus 로고
    • Obesity and disease management: Effects of weight loss on comorbid conditions
    • Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9(Suppl 4):326S-334S.
    • (2001) Obes Res , vol.9 , Issue.SUPPL. 4
    • Anderson, J.W.1    Konz, E.C.2
  • 13
    • 0032560807 scopus 로고    scopus 로고
    • Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
    • Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;23;339(4):229-234.
    • (1998) N Engl J Med , vol.23-339 , Issue.4 , pp. 229-234
    • Haffner, S.M.1    Lehto, S.2    Rönnemaa, T.3    Pyörälä, K.4    Laakso, M.5
  • 14
    • 33644696797 scopus 로고    scopus 로고
    • Type 2 diabetes as a "coronary heart disease equivalent": An 18-year prospective population-based study in Finnish subjects
    • Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28(12):2901-2907.
    • (2005) Diabetes Care , vol.28 , Issue.12 , pp. 2901-2907
    • Juutilainen, A.1    Lehto, S.2    Rönnemaa, T.3    Pyörälä, K.4    Laakso, M.5
  • 15
    • 0034641568 scopus 로고    scopus 로고
    • Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
    • Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
    • (2000) BMJ , vol.321 , Issue.7258 , pp. 405-412
    • Stratton, I.M.1    Adler, A.I.2    Neil, H.A.W.3
  • 16
    • 0032511580 scopus 로고    scopus 로고
    • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
    • UK Prospective Diabetes Study Group
    • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-713.
    • (1998) BMJ , vol.317 , Issue.7160 , pp. 703-713
  • 17
    • 0141988862 scopus 로고    scopus 로고
    • Importance of weight management in type 2 diabetes: Review with meta-analysis of clinical studies
    • Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22(5):331-339.
    • (2003) J Am Coll Nutr , vol.22 , Issue.5 , pp. 331-339
    • Anderson, J.W.1    Kendall, C.W.2    Jenkins, D.J.3
  • 18
    • 39149145482 scopus 로고    scopus 로고
    • Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004
    • Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol. 2008;18(3):222-229.
    • (2008) Ann Epidemiol , vol.18 , Issue.3 , pp. 222-229
    • Ong, K.L.1    Cheung, B.M.2    Wong, L.Y.3    Wat, N.M.4    Tan, K.C.5    Lam, K.S.6
  • 19
    • 77649091668 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus
    • AACE Diabetes Mellitus Clinical Practice Guidelines Task Force
    • Rodbard HW, Blonde L, Braithwaite SS, et al; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1-68.
    • (2007) Endocr Pract , vol.13 , Issue.SUPPL. 1 , pp. 1-68
    • Rodbard, H.W.1    Blonde, L.2    Braithwaite, S.S.3
  • 20
    • 50149089590 scopus 로고    scopus 로고
    • Evolving concepts of type 2 diabetes management with oral medications: New approaches to an old disease
    • Henry RR. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. Curr Med Res Opin. 2008;24(8):2189-2202.
    • (2008) Curr Med Res Opin , vol.24 , Issue.8 , pp. 2189-2202
    • Henry, R.R.1
  • 21
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study Group
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet. 1998;352(9131):837-853.
    • (1998) Lancet , vol.352 , Issue.9131 , pp. 837-853
  • 22
    • 54949131340 scopus 로고    scopus 로고
    • National trends in treatment of type 2 diabetes mellitus, 1994-2007
    • Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008;168(19):2088-2094.
    • (2008) Arch Intern Med , vol.168 , Issue.19 , pp. 2088-2094
    • Alexander, G.C.1    Sehgal, N.L.2    Moloney, R.M.3    Stafford, R.S.4
  • 23
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • United Kingdom Prospective Diabetes Study (UKPDS) Group
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). United Kingdom Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-865.
    • (1998) Lancet , vol.352 , Issue.9131 , pp. 854-865
  • 24
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowermg in type 2 diabetes
    • Action to Control Cardiovascular Risk in Diabetes Study Group
    • Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowermg in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
    • (2008) N Engl J Med , vol.358 , Issue.24 , pp. 2545-2559
    • Gerstein, H.C.1    Miller, M.E.2    Byington, R.P.3
  • 25
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    • ADVANCE Collaborative Group
    • ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
    • (2008) N Engl J Med , vol.358 , Issue.24 , pp. 2560-2572
    • Patel, A.1    MacMahon, S.2    Chalmers, J.3
  • 26
    • 58149389215 scopus 로고    scopus 로고
    • Glucose coLitrol and vascular complications in veterans with type 2 diabetes
    • VADT Investigators
    • Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose coLitrol and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
    • (2009) N Engl J Med , vol.360 , Issue.2 , pp. 129-139
    • Duckworth, W.1    Abraira, C.2    Moritz, T.3
  • 27
    • 63149103614 scopus 로고    scopus 로고
    • Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
    • American Diabetes Association; American College of Cardiology Foundation; American Heart Association
    • Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187-192.
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 187-192
    • Skyler, J.S.1    Bergenstal, R.2    Bonow, R.O.3
  • 28
    • 34447267513 scopus 로고    scopus 로고
    • Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
    • Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
    • (2007) JAMA , vol.298 , Issue.2 , pp. 194-206
    • Amori, R.E.1    Lau, J.2    Pittas, A.G.3
  • 29
    • 33644618433 scopus 로고    scopus 로고
    • The biology of incretin hormones
    • Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165.
    • (2006) Cell Metab , vol.3 , Issue.3 , pp. 153-165
    • Drucker, D.J.1
  • 30
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
    • (2006) Lancet , vol.368 , Issue.9548 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 31
    • 33845344395 scopus 로고
    • Plasma insulin response to oral and intravenous glucose administration
    • Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076-1082.
    • (1964) J Clin Endocrinol Metab , vol.24 , pp. 1076-1082
    • Elrick, H.1    Stimmler, L.2    Hlad Jr., C.J.3    Arai, Y.4
  • 32
    • 0014188893 scopus 로고
    • Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects
    • Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46(12):1954-1962.
    • (1967) J Clin Invest , vol.46 , Issue.12 , pp. 1954-1962
    • Perley, M.J.1    Kipnis, D.M.2
  • 33
    • 3242730474 scopus 로고    scopus 로고
    • Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
    • Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199-E206.
    • (2004) Am J Physiol Endocrinol Metab , vol.287 , Issue.2
    • Holst, J.J.1    Gromada, J.2
  • 34
    • 1842855423 scopus 로고    scopus 로고
    • Incretins, insulin secretion and type 2 diabetes mellitus
    • Vilsbøll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47(3):357-366.
    • (2004) Diabetologia , vol.47 , Issue.3 , pp. 357-366
    • Vilsbøll, T.1    Holst, J.J.2
  • 35
    • 0026535588 scopus 로고
    • Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells
    • Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992;130(1):159-166.
    • (1992) Endocrinology , vol.130 , Issue.1 , pp. 159-166
    • Fehmann, H.C.1    Habener, J.F.2
  • 36
    • 0036828227 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
    • Farilla L, Hui H, Bertolotto C. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143(11):4397-4408.
    • (2002) Endocrinology , vol.143 , Issue.11 , pp. 4397-4408
    • Farilla, L.1    Hui, H.2    Bertolotto, C.3
  • 37
    • 48749089599 scopus 로고    scopus 로고
    • Emerging incretin based therapies for type 2 diabetes: Incretin mimetics and DPP-4 inhibitors
    • Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev. 2008;4(2):101-109.
    • (2008) Curr Diabetes Rev , vol.4 , Issue.2 , pp. 101-109
    • Stonehouse, A.1    Okerson, T.2    Kendall, D.3    Maggs, D.4
  • 38
    • 0036959991 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
    • Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239-1246.
    • (2002) J Clin Endocrinol Metab , vol.87 , Issue.3 , pp. 1239-1246
    • Nauck, M.A.1    Heimesaat, M.M.2    Behle, K.3
  • 39
    • 0002300343 scopus 로고    scopus 로고
    • Glucagon-like peptide-1: A potent regulator of food intake in humans
    • Gutzwiller JP, Göke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999;44(1):81-86.
    • (1999) Gut , vol.44 , Issue.1 , pp. 81-86
    • Gutzwiller, J.P.1    Göke, B.2    Drewe, J.3
  • 40
    • 0027215348 scopus 로고
    • Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
    • Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829-835.
    • (1993) Eur J Biochem , vol.214 , Issue.3 , pp. 829-835
    • Mentlein, R.1    Gallwitz, B.2    Schmidt, W.E.3
  • 41
    • 0141446228 scopus 로고    scopus 로고
    • Enhancing incretin action for the treatment of type 2 diabetes
    • Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929-2940.
    • (2003) Diabetes Care , vol.26 , Issue.10 , pp. 2929-2940
    • Drucker, D.J.1
  • 42
    • 0029118049 scopus 로고
    • Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
    • Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136(8):3585-3596.
    • (1995) Endocrinology , vol.136 , Issue.8 , pp. 3585-3596
    • Kieffer, T.J.1    McIntosh, C.H.2    Pederson, R.A.3
  • 43
    • 0022617246 scopus 로고
    • Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
    • Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52.
    • (1986) Diabetologia , vol.29 , Issue.1 , pp. 46-52
    • Nauck, M.1    Stöckmann, F.2    Ebert, R.3    Creutzfeldt, W.4
  • 44
    • 0034880655 scopus 로고    scopus 로고
    • Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
    • Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723.
    • (2001) J Clin Endocrinol Metab , vol.86 , Issue.8 , pp. 3717-3723
    • Toft-Nielsen, M.B.1    Damholt, M.B.2    Madsbad, S.3
  • 45
    • 0027391607 scopus 로고
    • Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
    • Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301-307.
    • (1993) J Clin Invest , vol.91 , Issue.1 , pp. 301-307
    • Nauck, M.A.1    Heimesaat, M.M.2    Orskov, C.3    Holst, J.J.4    Ebert, R.5    Creutzfeldt, W.6
  • 46
    • 15444367142 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
    • Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62(2):173-181.
    • (2005) Am J Health Syst Pharm , vol.62 , Issue.2 , pp. 173-181
    • Kolterman, O.G.1    Kim, D.D.2    Shen, L.3
  • 47
    • 49849105507 scopus 로고    scopus 로고
    • The use of exenatide in islet transplant recipients with chronic allograft dysfunction: Safety, efficacy, and metabolic effects
    • Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008;86(1):36-45.
    • (2008) Transplantation , vol.86 , Issue.1 , pp. 36-45
    • Froud, T.1    Faradji, R.N.2    Pileggi, A.3
  • 48
    • 0036312680 scopus 로고    scopus 로고
    • Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4
    • Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002;51(5):1443-1452.
    • (2002) Diabetes , vol.51 , Issue.5 , pp. 1443-1452
    • Tourrel, C.1    Bailbe, D.2    Lacorne, M.3    Meile, M.J.4    Kergoat, M.5    Portha, B.6
  • 49
    • 65949122087 scopus 로고    scopus 로고
    • One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial
    • Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32(5):762-768.
    • (2009) Diabetes Care , vol.32 , Issue.5 , pp. 762-768
    • Bunck, M.C.1    Diamant, M.2    Cornér, A.3
  • 50
    • 7444228521 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    • Exenatide-113 Clinical Study Group
    • Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-2635.
    • (2004) Diabetes Care , vol.27 , Issue.11 , pp. 2628-2635
    • Buse, J.B.1    Henry, R.R.2    Han, J.3    Kim, D.D.4    Fineman, M.S.5    Baron, A.D.6
  • 51
    • 33947156808 scopus 로고    scopus 로고
    • Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    • Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29(1):139-153.
    • (2007) Clin Ther , vol.29 , Issue.1 , pp. 139-153
    • Buse, J.B.1    Klonoff, D.C.2    Nielsen, L.L.3
  • 52
    • 17144371646 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    • Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-1091.
    • (2005) Diabetes Care , vol.28 , Issue.5 , pp. 1083-1091
    • Kendall, D.M.1    Riddle, M.C.2    Rosenstock, J.3
  • 53
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    • DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100.
    • (2005) Diabetes Care , vol.28 , Issue.5 , pp. 1092-1100
    • DeFronzo, R.A.1    Ratner, R.E.2    Han, J.3    Kim, D.D.4    Fineman, M.S.5    Baron, A.D.6
  • 54
    • 34247259577 scopus 로고    scopus 로고
    • The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial
    • Zinman B, Hoogwerf BJ, Durán Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477-185.
    • (2007) Ann Intern Med , vol.146 , Issue.7 , pp. 477-1185
    • Zinman, B.1    Hoogwerf, B.J.2    Durán Garcia, S.3
  • 55
    • 37349008890 scopus 로고    scopus 로고
    • Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
    • Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333-2348.
    • (2007) Clin Ther , vol.29 , Issue.11 , pp. 2333-2348
    • Barnett, A.H.1    Burger, J.2    Johns, D.3
  • 56
    • 41149104495 scopus 로고    scopus 로고
    • Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: A pooled post-hoc analysis
    • Glass LC, Qu Y, Lenox S, et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin. 2008;24(3):639-644.
    • (2008) Curr Med Res Opin , vol.24 , Issue.3 , pp. 639-644
    • Glass, L.C.1    Qu, Y.2    Lenox, S.3
  • 57
    • 26944477362 scopus 로고    scopus 로고
    • Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
    • GWAA Study Group
    • Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559-569.
    • (2005) Ann Intern Med , vol.143 , Issue.8 , pp. 559-569
    • Heine, R.J.1    Van Gaal, L.F.2    Johns, D.3    Mihm, M.J.4    Widel, M.H.5    Brodows, R.G.6
  • 58
    • 34247195226 scopus 로고    scopus 로고
    • A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study
    • Nauck MA, Duran S, Kim D. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259-267.
    • (2007) Diabetologia , vol.50 , Issue.2 , pp. 259-267
    • Nauck, M.A.1    Duran, S.2    Kim, D.3
  • 59
    • 74249123519 scopus 로고    scopus 로고
    • Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks inpatients with type 2 diabetes
    • Abstract 1239
    • Bergenstal RM, Kim T, Trautmann M, Zhuang D, Okerson T, Taylor K. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks inpatients with type 2 diabetes. Circulation. 2008;118(Suppl 1):S1086. Abstract 1239.
    • (2008) Circulation , vol.118 , Issue.SUPPL. 1
    • Bergenstal, R.M.1    Kim, T.2    Trautmann, M.3    Zhuang, D.4    Okerson, T.5    Taylor, K.6
  • 60
    • 55549136417 scopus 로고    scopus 로고
    • Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study
    • DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943-2952.
    • (2008) Curr Med Res Opin , vol.24 , Issue.10 , pp. 2943-2952
    • DeFronzo, R.A.1    Okerson, T.2    Viswanathan, P.3    Guan, X.4    Holcombe, J.H.5    MacConell, L.6
  • 61
    • 53249142132 scopus 로고    scopus 로고
    • Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study
    • DURATION-1 Study Group
    • Drucker DJ, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
    • (2008) Lancet , vol.372 , Issue.9645 , pp. 1240-1250
    • Drucker, D.J.1    Buse, J.B.2    Taylor, K.3
  • 62
    • 34249891874 scopus 로고    scopus 로고
    • Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
    • Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487-1493.
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1487-1493
    • Kim, D.1    MacConell, L.2    Zhuang, D.3
  • 63
    • 38549162147 scopus 로고    scopus 로고
    • Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    • Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275-286.
    • (2008) Curr Med Res Opin , vol.24 , Issue.1 , pp. 275-286
    • Klonoff, D.C.1    Buse, J.B.2    Nielsen, L.L.3
  • 64
    • 51549095571 scopus 로고    scopus 로고
    • Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
    • Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448-1460.
    • (2008) Clin Ther , vol.30 , Issue.8 , pp. 1448-1460
    • Moretto, T.J.1    Milton, D.R.2    Ridge, T.D.3
  • 65
    • 33344477581 scopus 로고    scopus 로고
    • Polypharmacy as a risk factor in the treatment of type 2 diabetes
    • Austin RP. Polypharmacy as a risk factor in the treatment of type 2 diabetes. Diabetes Spectrum. 2006;19(1):13-16.
    • (2006) Diabetes Spectrum , vol.19 , Issue.1 , pp. 13-16
    • Austin, R.P.1
  • 66
    • 27744511416 scopus 로고    scopus 로고
    • The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes)
    • Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7(6):722-728.
    • (2005) Diabetes Obes Metab , vol.7 , Issue.6 , pp. 722-728
    • Kardas, P.1
  • 67
    • 0030815747 scopus 로고    scopus 로고
    • Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: A randomized clinical trial using electronic monitoring
    • Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13(10):914-920.
    • (1997) Can J Cardiol , vol.13 , Issue.10 , pp. 914-920
    • Leenen, F.H.1    Wilson, T.W.2    Bolli, P.3
  • 68
    • 59449101432 scopus 로고    scopus 로고
    • Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomized, 52-week, phase III, double-blind, parallel-treatment trial
    • LEAD-3 (Mono) Study Group
    • Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481.
    • (2009) Lancet , vol.373 , Issue.9662 , pp. 473-481
    • Garber, A.1    Henry, R.2    Ratner, R.3
  • 69
    • 62449129181 scopus 로고    scopus 로고
    • Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
    • LEAD-1 SU study group
    • Marre M, Shaw J, Brändle M, et al; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268-278.
    • (2009) Diabet Med , vol.26 , Issue.3 , pp. 268-278
    • Marre, M.1    Shaw, J.2    Brändle, M.3
  • 70
    • 62449169287 scopus 로고    scopus 로고
    • Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study
    • LEAD-2 Study Group
    • Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90.
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 84-90
    • Nauck, M.1    Frid, A.2    Hermansen, K.3
  • 71
    • 47649094517 scopus 로고    scopus 로고
    • Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
    • Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):161-168.
    • (2008) Diabetes Res Clin Pract , vol.81 , Issue.2 , pp. 161-168
    • Seino, Y.1    Rasmussen, M.F.2    Zdravkovic, M.3    Kaku, K.4
  • 72
    • 34249869806 scopus 로고    scopus 로고
    • Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
    • Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608-1610.
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1608-1610
    • Vilsbøll, T.1    Zdravkovic, M.2    Le-Thi, T.3
  • 73
    • 50649110233 scopus 로고    scopus 로고
    • Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes
    • Courrèges JP, Vilsbøll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med. 2008;25(9):1129-1131.
    • (2008) Diabet Med , vol.25 , Issue.9 , pp. 1129-1131
    • Courrèges, J.P.1    Vilsbøll, T.2    Zdravkovic, M.3
  • 74
    • 65349161010 scopus 로고    scopus 로고
    • Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
    • Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol. 2009;8:12.
    • (2009) Cardiovasc Diabetol , vol.8 , pp. 12
    • Sullivan, S.D.1    Alfonso-Cristancho, R.2    Conner, C.3    Hammer, M.4    Blonde, L.5
  • 76
    • 63149173251 scopus 로고    scopus 로고
    • Standards of medical care in diabetes - 2009
    • American Diabetes Association
    • American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.
    • (2009) Diabetes Care , vol.32 , Issue.SUPPL. 1
  • 77
    • 40749106934 scopus 로고    scopus 로고
    • Managing multiple cardiovascular risk factors
    • Blank RC, Brunton S. Managing multiple cardiovascular risk factors. J Fam Pract. 2008;57(3 Suppl):S13-S20.
    • (2008) J Fam Pract , vol.57 , Issue.3 SUPPL.
    • Blank, R.C.1    Brunton, S.2
  • 78
    • 64749100501 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • American Diabetes Association; European Association for Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.